Two medicines, side by side
Amlodipine vs rosuvastatin
Amlodipine and rosuvastatin are both labeled for heart attack and coronary artery disease. Drugs@FDA records approvals of amlodipine since 1992 and of rosuvastatin since 2003. Pharmacies paid $0.0102 per amlodipine besylate 5 mg tablet and $0.0692 per rosuvastatin calcium 40 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, amlodipine is a calcium channel blocker and rosuvastatin a hmg-coa reductase inhibitor.
Check it at the source: the amlodipine FDA label on DailyMed (effective February 15, 2023); the rosuvastatin FDA label on DailyMed (effective September 4, 2026).
Highlights of the amlodipine record
Amlodipine (Norvasc) · label of February 15, 2023
Used for
From the label: indicationsNORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: • Hypertension ( 1.1 ) o NORVASC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. […]
On the market
- Earliest approval on file
- July 31, 1992
- Generic labelers
- 42 labelers
- Pharmacy cost
- $0.0102 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 30
Highlights of the rosuvastatin record
Rosuvastatin (Crestor) · label of September 4, 2026
Used for
From the label: indicationsRosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults at increased risk for CV events. […]
On the market
- Earliest approval on file
- August 12, 2003
- Generic labelers
- 45 labelers
- Pharmacy cost
- $0.0692 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 13
Source: FDA drug labels via openFDA (Amlodipine label of February 15, 2023, Rosuvastatin label of September 4, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do amlodipine and rosuvastatin differ on the record?
In FDA's classes, amlodipine is a calcium channel blocker and rosuvastatin a hmg-coa reductase inhibitor.
How each works, in its label's words: Amlodipine, “Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac …”; Rosuvastatin, “Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.”
Generics: amlodipine since 2005; rosuvastatin since 2016 (Drugs@FDA).
| Amlodipine | Rosuvastatin | |
|---|---|---|
| Labeled for | High blood pressure, Angina, Heart attack and coronary artery disease | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Pharmacologic class | Calcium Channel Blocker, Dihydropyridine Calcium Channel Blocker | HMG-CoA Reductase Inhibitor |
| How it works (label) | Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow‑channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. | Rosuvastatin is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. |
| Half-life (label) | n/a | The elimination half-life of rosuvastatin is approximately 19 hours. |
| Earliest approval on file (Drugs@FDA) | July 31, 1992 | August 12, 2003 |
| First generic approved | October 3, 2005 | April 29, 2016 |
| Generic labelers (NDC) | 42 labelers | 45 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.0102 per tablet (Amlodipine besylate 5 mg tablet) | $0.0692 per tablet (Rosuvastatin calcium 40 mg tablet) |
| 12-month price change | -10% | -7% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 30 | 13 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 409,186 | 110,043 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to amlodipine
- every medicine labeled for the same conditions